Tp53-associated pediatric malignancies

Genes and Cancer

Volumn 2, Issue 4, 2011, Pages 485-490

  Pinto, Emilia M ^a   Ribeiro, Raul C ^a,b   Figueiredo, Bonald C ^c   Zambetti, Gerard P ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c INSTITUTO DE PESQUISA PELÉ PEQUENO PRÍNCIPE   (Brazil)

Author keywords

adrenocortical tumors; Arg337His; p53 mutation

Indexed keywords

PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ALLELE; ARTICLE; CANCER INHIBITION; CANCER REGISTRY; CANCER RISK; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 80053030840     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911409745     Document Type: Article

References (67)

1. AltekruseSFKosaryCLKrapchoM, editors. SEER Cancer Statistics Review, 1975-2007, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/.
2. Strong LC,Williams WR,Tainsky MA.The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics.Am J Epidemiol. 1992;135:190-9.
3. Birch JM,Blair V,Kelsey AM, et al.Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.Oncogene. 1998;17:1061-8.
4. Bennett WP,Hussain SP,Vahakangas KH,Khan MA,Shields PG,Harris CC.Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer.J Pathol. 1999;187:8-18.
5. Vousden KH,Lane DP.p53 in health and disease.Nat Rev Mol Cell Biol. 2007;8:275-83.
6. Brosh R,Rotter V.When mutants gain new powers: news from the mutant p53 field.Nat Rev Cancer. 2009;9:701-13.
7. Oren M.Decision making by p53: life, death and cancer.Cell Death Differ. 2003;10:431-42.
8. Vousden KH,Lu X.Live or let die: the cell's response to p53.Nat Rev Cancer. 2002;2:594-604.
9. Weisz L,Oren M,Rotter V.Transcription regulation by mutant p53.Oncogene. 2007;26:2202-11.
10. Yan W,Chen X.Characterization of functional domains necessary for mutant p53 gain of function.J Biol Chem. 2010;285:14229-38.
11. Zambetti GP.The p53 mutation "gradient effect" and its clinical implications.J Cell Physiol. 2007;213:370-3.
12. Petitjean A,Mathe E,Kato S, et al.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.Hum Mutat. 2007;28:622-9.
13. Latronico AC,Pinto EM,Domenice S, et al.An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors.J Clin Endocrinol Metab. 2001;86:4970-3.
14. Ribeiro RC,Sandrini F,Figueiredo B, et al.An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.Proc Natl Acad Sci U S A. 2001;98:9330-5.
15. Pinto EM,Ribeiro RC,Kletter GB, et al.Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor.Fam Cancer. 2011;10:141-6.
16. Milner J,Medcalf EA.Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.Cell. 1991;65:765-74.
17. de Vries A,Flores ER,Miranda B, et al.Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.Proc Natl Acad Sci U S A. 2002;99:2948-53.
18. Russell-Swetek A,West AN,Mintern JE, et al.Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.J Med Genet. 2008;45:603-6.
19. Liu G,McDonnell TJ,Montes de Oca Luna R, et al.High metastatic potential in mice inheriting a targeted p53 missense mutation.Proc Natl Acad Sci U S A. 2000;97:4174-9.
20. Momand J,Zambetti GP,Olson DC,George D,Levine AJ.The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.Cell. 1992;69:1237-45.
21. Haupt Y,Maya R,Kazaz A,Oren M.Mdm2 promotes the rapid degradation of p53.Nature. 1997;387:296-9.
22. Wade M,Wahl GM.Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?.Mol Cancer Res. 2009;7:1-11.
23. Bond GL,Hu W,Bond EE, et al.A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.Cell. 2004;119:591-602.
24. Bougeard G,Baert-Desurmont S,Tournier I, et al.Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.J Med Genet. 2006;43:531-3.
25. Shvarts A,Steegenga WT,Riteco N, et al.MDMX: a novel p53-binding protein with some functional properties of MDM2.EMBO J. 1996;15:5349-57.
26. Reed D,Shen Y,Shelat AA, et al.Identification and characterization of the first small molecule inhibitor of MDMX.J Biol Chem. 2010;285:10786-96.
27. Laurie NA,Donovan SL,Shih CS, et al.Inactivation of the p53 pathway in retinoblastoma.Nature. 2006;444:61-6.
28. Li FP,Fraumeni JF,Mulvihill JJ, et al.A cancer family syndrome in twenty-four kindreds.Cancer Res. 1998;48:5358-62.
29. Lustbader ED,Williams WR,Bondy ML,Strom S,Strong LC.Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.Am J Hum Genet. 1992;51:344-56.
30. Gonzalez KD,Noltner KA,Buzin CH, et al.Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations.J Clin Oncol. 2009;27:1250-6.
31. Olivier M,Goldgar DE,Sodha N, et al.Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.Cancer Res. 2003;63:6643-50.
32. Birch JM.Familial cancer syndromes and clusters.Br Med Bull. 1994;50:624-39.
33. Chompret A,Abel A,Stoppa-Lyonnet D, et al.Sensitivity and predictive value of criteria for p53 germline mutation screening.J Med Genet. 2001;38:43-7.
34. Birch JM,Hartley AL,Tricker KJ, et al.Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.Cancer Res. 1994;54:1298-304.
35. Varley JM.Germline TP53 mutations and Li-Fraumeni syndrome.Hum Mutat. 2003;21:313-20.
36. Jemal A,Murray T,Samuels A,Ghafoor A,Ward E,Thun MJ.Cancer statistics, 2003.CA Cancer J Clin. 2003 2003;53:5-26.
37. Munir CS, Nectoux J. International patterns of cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York: Oxford University Press; 1996. p. 141-67.
38. Teinturier C,Pauchard MS,Brugieres L,Landais P,Chaussain JL,Bougneres PF.Clinical and prognostic aspects of adrenocortical neoplasms in childhood.Med Pediatr Oncol. 1999;32:106-11.
39. Langer P,Cupisti K,Bartsch DK, et al.Adrenal involvement in multiple endocrine neoplasia type 1.World J Surg. 2002;26:891-6.
40. Rosati R,Cerrato F,Doghman M, et al.High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation.Cancer Genet Cytogenet. 2008;186:19-24.
41. Wagner J,Portwine C,Rabin K,Leclerc JM,Narod SA,Malkin D.High frequency of germline p53 mutations in childhood adrenocortical cancer.J Natl Cancer Inst. 1994;86:1707-10.
42. Michalkiewicz E,Sandrini R,Figueiredo B, et al.Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.J Clin Oncol. 2004;22:838-45.
43. West AN,Ribeiro RC,Jenkins J, et al.Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma.Cancer Res. 2006;66:5056-62.
44. Varley JM,McGown G,Thorncroft M, et al.Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors.Am J Hum Genet. 1999;65:995-1006.
45. Pianovski MA,Maluf EM,de Carvalho DS, et al.Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil.Pediatr Blood Cancer. 2006;47:56-60.
46. DiGiammarino EL,Lee AS,Cadwell C, et al.A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer.Nat Struct Biol. 2002;9:12-6.
47. Lomax ME,Barnes DM,Hupp TR,Picksley SM,Camplejohn RS.Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.Oncogene. 1998;17:643-9.
48. Davison TS,Yin P,Nie E,Kay C,Arrowsmith CH.Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.Oncogene. 1998;7:651-6.
49. Seidinger AL,Mastellaro MJ,Fortes FP, et al.Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil.Cancer. 2010;:.
50. Assumpcao JG,Seidinger AL,Mastellaro MJ, et al.Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.BMC Cancer. 2008;8:357.
51. Oliveira CR,Mendonca BB,Camargo OP, et al.Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters.Clinics (Sao Paulo). 2007;62:167-74.
52. McIntyre JF,Smith-Sorensen B,Friend SH, et al.Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.J Clin Oncol. 1994;12:925-30.
53. Figueiredo BC,Sandrini R,Zambetti GP, et al.Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation.J Med Genet. 2006;43:91-6.
54. Pinto EM,Billerbeck AE,Fragoso MC,Mendonca BB,Latronico AC.Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein.J Clin Endocrinol Metab. 2005;90:2976-81.
55. Pinto EM,Billerbeck AE,Villares MC,Domenice S,Mendonca BB,Latronico AC.Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors.Arq Bras Endocrinol Metabol. 2004;48:647-50.
56. Parra FC,Amado RC,Lambertucci JR,Rocha J,Antunes CM,Pena SD.Color and genomic ancestry in Brazilians.Proc Natl Acad Sci U S A. 2003;100:177-82.
57. Giordano TJ,Thomas DG,Kuick R, et al.Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.Am J Pathol. 2003;162:521-31.
58. Velazquez-Fernandez D,Laurell C,Geli J, et al.Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy.Surgery. 2005;138:1087-94.
59. West AN,Neale GA,Pounds S, et al.Gene expression profiling of childhood adrenocortical tumors.Cancer Res. 2007;67:600-8.
60. Han VK,Lund PK,Lee DC,D'Ercole AJ.Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution.J Clin Endocrinol Metab. 1998;66:422-9.
61. Figueiredo BC,Stratakis CA,Sandrini R, et al.Comparative genomic hybridization analysis of adrenocortical tumors of childhood.J Clin Endocrinol Metab. 1999;84:1116-21.
62. Figueiredo BC,Cavalli LR,Pianovski MA, et al.Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors.J Clin Endocrinol Metab. 2005;90:615-9.
63. Pianovski MA,Cavalli LR,Figueiredo BC, et al.SF-1 overexpression in childhood adrenocortical tumours.Eur J Cancer. 2006;42:1040-3.
64. Parker KL,Schimmer BP.Steroidogenic factor 1: a key determinant of endocrine development and function.Endocr Rev. 1997;18:361-77.
65. Doghman M,Karpova T,Rodrigues GA, et al.Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer.Mol Endocrinol. 2007;21:2968-87.
66. Matzuk MM,Finegold MJ,Mather JP,Krummen L,Lu H,Bradley A.Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice.Proc Natl Acad Sci U S A. 1994;91:8817-21.
67. Longui CA,Lemos-Marini SH,Figueiredo B, et al.Inhibin alpha-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers.J Med Genet. 2004;41:354-9.